Sotatercept has been approved for use in eligible patients in England and Wales. The decision by the National Institute for Health and Care Excellence (NICE), announced on 14th May, means the drug (brand name Winrevair®) can be prescribed alongside existing pulmonary arterial hypertension treatments for patients who meet specific clinical criteria. The drug was approved in Scotland by the Scottish Medicines Consortium in April, and Northern Ireland will make its own separate decision in due course – taking the National Institute for Health and Care Excellence recommendation into account.
Sotatercept will not be available for prescription immediately. National Health Service (NHS) commissioning must be put in place – a process that can take up to 90 days in England and 60 days in Wales.
Read more at this link on the PHA UK website